Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
Cancer patients with mutations or variations in two genes -– PIK3CA and PTEN -– who have failed to respond to several, standard treatments, respond significantly better to anti-cancer drugs that inhibit these genes' pathways of action, according to research presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today.
Dr Filip Janku (MD, PhD), assistant professor in Investigational Cancer Therapeutics at MD Anderson Cancer Center (Houston, USA), told the meeting that mutations in PIK3CA and aberrations (loss of function or mutation) in PTEN were present in a wide range of tumours and were thought to be involved in the development of cancer. These genes act via a pathway known as the PI3K/AKT/mTOR pathway, and so inhibiting the pathway could improve the patients' response to treatment.
The researchers tested 1656 patients with a variety of cancers and found that 146 (9%) had PIK3CA mutations, 150 (13%) had PTEN aberrations and 14 (1%) had both.
They treated 134 of the patients who had PIK3CA mutations, PTEN aberrations or both in early-phase clinical trials that included drugs that block the PI3K/AKT/mTOR pathway. The patients had failed an average of three, previous treatments. Of these patients, 107 were also tested for mutations in another, known cancer-causing gene, KRAS.
Dr Janku said: "We found that heavily pre-treated patients with PIK3CA mutations, PTEN aberrations, or both had a significantly higher response rate on protocols incorporating PI3K/AKT/mTOR inhibitors compared to patients without known PIK3CA/PTEN aberrations treated on the same protocols. In addition, we noticed that patients who had these and also simultaneous mutation in codons 12 or 13 of KRAS (which is a likely mechanism of drug resistance) did not respond to protocols with PI3K/AKT/mTOR inhibitors.
"Furthermore, it looks as if treatment with a single agent may not be sufficient, as patients with PIK3CA mutations and/or PTEN aberrations treated with drug combinations that included PI3K/AKT/mTOR inhibitors had higher response rate than patients treated with PI3K/AKT/mTOR inhibitors alone."
Of the patients who were treated with PI3K/AKT/mTOR inhibitors, 23 out of 134 (17%) had a partial response to the therapy (where the tumour shrinks by at least 30%) and 9 out of 134 (7%) had stable disease for six months or more, while only 26 out of 458 patients (6%) without a PIK3CA mutation or PTEN aberration had a partial response when treated with the same therapies. Of the 26 patients who also had a KRAS mutation in codons 12 or 13, only one (4%) had a partial response, compared to 18 out of 81 (22%) of patients without the KRAS mutation. Among the patients treated with a single agent, PI3K/AKT/mTOR inhibitor, only one out of 40 (2.5%) had a partial response to the treatment compared to 22 out of 94 (23%) of the patients treated with a combination of agents, including a PI3K/AKT/mTOR inhibitor.
Dr Janku said: "These results suggest that heavily pre-treated patients with mutations or aberrations in PIK3CA, PTEN or both are more likely to have tumours that respond and shrink when they are treated with a combination of drugs that include PI3K/AKT/mTOR inhibitors, compared with patients treated the same way but whose PIK3CA and PTEN status is unknown. Therefore, screening for these mutations and aberrations, as well as KRAS mutations, can make treatments with PI3K/AKT/mTOR inhibitors more effective for patients."
He said that further investigation was required as the study had several limitations that included the fact that the patients had a variety of cancers, received diverse treatments, were treated on different dose levels and the study was not randomised. "Our findings warrant further prospective investigation especially since many PI3K/AKT/mTOR inhibitors are entering the clinical arena."
There are a number of PI3K/AKT/mTOR inhibitors currently being developed; however, none of the ones that inhibit the PI3K or AKT have been approved yet for use in the clinic. Examples of mTOR inhibitors that have been approved for treatment of cancers include temsirolimus and everolimus.
Professor Stefan Sleijfer, the scientific chair of the EORTC-NCI-AACR Symposium, from Erasmus University Medical Centre (The Netherlands), commented: "This study is interesting because it provides important hints as to how we can select cancer patients who are likely to benefit from PI3K/AKT/mTOR inhibitor-containing regimens. If confirmed, this may be the way to come to a more personalised treatment approach with these compounds."
More information: Abstract no: 246. Proffered papers, plenary session 6, 15.00 hrs, Thursday 8 November.
Provided by ECCO-the European CanCer Organisation
- Genetic approach provides new insight into trastuzumab resistance in breast cancer Oct 15, 2007 | not rated yet | 0
- Combination therapies for drug-resistant cancers Oct 10, 2011 | not rated yet | 0
- Predicting drug responsiveness in cancer patients Jul 26, 2010 | not rated yet | 0
- Therapy exploits 'addiction' of leukemia cells Apr 16, 2012 | not rated yet | 0
- PI3K/mTOR pathway proteins tied to poor prognosis in breast cancer Apr 01, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
5 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...
Cancer 17 minutes ago | not rated yet | 0 |
More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.
Cancer 57 minutes ago | not rated yet | 0
(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...
Cancer 1 hour ago | not rated yet | 0 |
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer 15 hours ago | not rated yet | 0
National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...
Cancer 15 hours ago | not rated yet | 0
(Medical Xpress)—Scientists at Emory Vaccine Center have shown that an immune regulatory molecule called IL-21 is needed for long-lasting antibody responses in mice against viral infections.
1 hour ago | not rated yet | 0 |
As health services strive to improve quality and reduce costs, researchers study the benefits – and the pitfalls – of 'pay for performance' in hospitals.
26 minutes ago | not rated yet | 0 |
(Medical Xpress)—According to the World Health Organization, approximately 70 million couples experience infertility worldwide. Current data suggests that nearly one third of infertility disorders are due ...
37 minutes ago | not rated yet | 0
(Medical Xpress)—There is no significant risk directly associated with air travel during pregnancy, even at advanced gestation, says report by the University of Liverpool.
47 minutes ago | not rated yet | 0
To coincide with the broadcast of Jabbed: Love, Fear and Vaccines (SBS ONE, Sunday 26 May at 8.30pm) the first ever national survey on Australian attitudes to vaccination reveals surprising statistics including half of Australians ...
1 hour ago | not rated yet | 0
A study from the June issue of Anesthesiology found feedback from the front region of the brain is a crucial building block for consciousness and that its disruption is associated with unconsciousness when the anesthetics ketami ...
17 minutes ago | not rated yet | 0